Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Apr;39(4):882–886. doi: 10.1128/aac.39.4.882

Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria.

M A Polis 1, K M Spooner 1, B F Baird 1, J F Manischewitz 1, H S Jaffe 1, P E Fisher 1, J Falloon 1, R T Davey Jr 1, J A Kovacs 1, R E Walker 1, et al.
PMCID: PMC162647  PMID: 7785989

Abstract

Cidofovir (HPMPC; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine) is a nucleotide analog with activity against human cytomegalovirus (CMV). A phase I/II dose escalation trial was conducted with asymptomatic human immunodeficiency virus (HIV)-infected patients with CMV viruria to determine its pharmacokinetics, maximally tolerated dose, and preliminary antiviral activity against CMV. Qualitative CMV blood and urine cultures were monitored weekly to assess anti-CMV activity. Twenty-one HIV-infected persons with CD4 counts from 0 to 389 cells per microliters (median, 39) were enrolled in six dose-ranging groups. The first five groups enrolled four patients each to receive cidofovir infusions either weekly or biweekly for 4 weeks or every 3 weeks for 12 weeks. The sixth group enrolled one patient who received infusions of 5 mg/kg of body weight every other week. Patients receiving 0.5 or 1.5 mg/kg twice weekly experienced no serious toxicity. The first two patients who received 5 mg/kg twice weekly developed glycosuria and 2+ proteinuria. Subsequent patients received concomitant probenecid to attempt to ameliorate renal toxicity. Seventeen patients experienced proteinuria on one or more occasions; 6 of them experienced at least 2+ proteinuria. Four patients did not complete the study as planned because of renal toxicity. Positive CMV urine cultures reverted to negative in 2 of 8 patients receiving doses of < or = 1.5 mg/kg twice weekly and 11 of 13 patients receiving higher doses. Cidofovir has in vivo anti-CMV activity demonstrated by prolonged clearing of CMV viruria, although this observation is tempered by the fact that clearance of viremia could not be demonstrated. The dose-limiting toxicity is renal; however, concurrent administration of probenecid may be protective. The maximally tolerated weekly intravenous dose with probenecid is approximately 5 mg/kg. Efficacy trials with CMV disease will define the therapeutic utility and optimal dosing interval for cidofovir.

Full Text

The Full Text of this article is available as a PDF (182.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bronson J. J., Ghazzouli I., Hitchcock M. J., Webb R. R., 2nd, Martin J. C. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem. 1989 Jul;32(7):1457–1463. doi: 10.1021/jm00127a010. [DOI] [PubMed] [Google Scholar]
  2. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., Holý A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 1987 Dec;8(5-6):261–272. doi: 10.1016/s0166-3542(87)80004-9. [DOI] [PubMed] [Google Scholar]
  3. Drew W. L., Miner R. C., Busch D. F., Follansbee S. E., Gullett J., Mehalko S. G., Gordon S. M., Owen W. F., Jr, Matthews T. R., Buhles W. C. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991 Apr;163(4):716–719. doi: 10.1093/infdis/163.4.716. [DOI] [PubMed] [Google Scholar]
  4. Glassock R. J., Cohen A. H., Danovitch G., Parsa K. P. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med. 1990 Jan 1;112(1):35–49. doi: 10.7326/0003-4819-112-1-35. [DOI] [PubMed] [Google Scholar]
  5. Herskowitz A., Willoughby S. B., Baughman K. L., Schulman S. P., Bartlett J. D. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med. 1992 Feb 15;116(4):311–313. doi: 10.7326/0003-4819-116-4-311. [DOI] [PubMed] [Google Scholar]
  6. Hoover D. R., Saah A. J., Bacellar H., Phair J., Detels R., Anderson R., Kaslow R. A. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med. 1993 Dec 23;329(26):1922–1926. doi: 10.1056/NEJM199312233292604. [DOI] [PubMed] [Google Scholar]
  7. Moore M. R., Hamzeh F. M., Lee F. E., Lietman P. S. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system. Antimicrob Agents Chemother. 1994 Oct;38(10):2404–2408. doi: 10.1128/aac.38.10.2404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Neyts J., Snoeck R., Balzarini J., De Clercq E. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Antiviral Res. 1991 Jul;16(1):41–52. doi: 10.1016/0166-3542(91)90057-x. [DOI] [PubMed] [Google Scholar]
  9. Neyts J., Snoeck R., Schols D., Balzarini J., De Clercq E. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology. 1990 Nov;179(1):41–50. doi: 10.1016/0042-6822(90)90271-r. [DOI] [PubMed] [Google Scholar]
  10. Palestine A. G., Polis M. A., De Smet M. D., Baird B. F., Falloon J., Kovacs J. A., Davey R. T., Zurlo J. J., Zunich K. M., Davis M. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991 Nov 1;115(9):665–673. doi: 10.7326/0003-4819-115-9-665. [DOI] [PubMed] [Google Scholar]
  11. Petty B. G., Kornhauser D. M., Lietman P. S. Zidovudine with probenecid: a warning. Lancet. 1990 Apr 28;335(8696):1044–1045. doi: 10.1016/0140-6736(90)91116-r. [DOI] [PubMed] [Google Scholar]
  12. Quinnan G. V., Jr, Masur H., Rook A. H., Armstrong G., Frederick W. R., Epstein J., Manischewitz J. F., Macher A. M., Jackson L., Ames J. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA. 1984 Jul 6;252(1):72–77. [PubMed] [Google Scholar]
  13. Salmon D., Lacassin F., Harzic M., Leport C., Perronne C., Bricaire F., Brun-Vezinet F., Vilde J. L. Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS. J Med Virol. 1990 Nov;32(3):160–163. doi: 10.1002/jmv.1890320306. [DOI] [PubMed] [Google Scholar]
  14. Soike K. F., Huang J. L., Zhang J. Y., Bohm R., Hitchcock M. J., Martin J. C. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (S-HPMPC) on simian varicella infection in monkeys. Antiviral Res. 1991 Jul;16(1):17–28. doi: 10.1016/0166-3542(91)90055-v. [DOI] [PubMed] [Google Scholar]
  15. Stals F. S., de Clercq E., Bruggeman C. A. Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo. Antimicrob Agents Chemother. 1991 Nov;35(11):2262–2266. doi: 10.1128/aac.35.11.2262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Zurlo J. J., O'Neill D., Polis M. A., Manischewitz J., Yarchoan R., Baseler M., Lane H. C., Masur H. Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med. 1993 Jan 1;118(1):12–17. doi: 10.7326/0003-4819-118-1-199301010-00003. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES